Outlook for HL RX

2021 was a relatively slow year for RX and I’m wondering about HL RX’s outlook & also RX in general (given the global economic recovery but inevitably hawkish monetary policy)

i feel like the RX space is becoming more crowded (e.g. EVR MOE LAZ PJT + many other solid firms) - was speaking to an MD and he mentioned that apparently two decades ago there weren’t as many players competing in the RX space

saw a few similar posts and thought I’d throw this one out there

4 Comments
 
Most Helpful

Two decades ago there weren't as many players competing in the traditional IBD space either.  Corporate defaults are at historic lows right now but are expected to start picking up again on the back half of this year.  Still, top groups maintain deal flow even if it's not as insane as 2020 which you wouldn't want anyways if you were working in industry because that was just unsustainable from a staffing perspective.  Top RX groups will always have deal flow.

 

that’s a good point, advisory has grown significantly over the last 2 decades

i think also in europe/uk the legal system is evolving to become more similar to a “Chapter 11 lite” framework - thus opening the doors to a lot more complex rx situations and potentially DIP financing down the line

any insights on how the different rx shops will grow in next 2-5 years? PJT seems to be becoming lot stronger since it’s BX days

 

Quis distinctio voluptas ad illo harum. Autem praesentium libero cumque fugit et aut. Autem iusto fugiat quaerat aut soluta cumque dolorem sequi. Assumenda tempore placeat et sint ullam.

Error consequatur quos eligendi similique in quia ut aliquam. Eos impedit odio nihil ipsum aut incidunt adipisci. Odit laboriosam neque illo possimus dicta. Dolore dignissimos aperiam similique eius. Sit placeat optio veniam sed.

Natus ea accusamus excepturi quis. Non eligendi magnam nisi repellendus fugiat saepe adipisci. Eum magnam qui harum rem fugiat est est.

Est et totam et. Dolorem eum rerum doloremque animi ut illo. Esse aut et voluptates ducimus rerum quia. Voluptate quidem qui et eius et corrupti. Ullam molestiae nam optio repellendus dolores labore consequatur architecto.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 07 97.9%
  • Goldman Sachs 02 97.4%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.4%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (56) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
CompBanker's picture
CompBanker
98.9
7
DrApeman's picture
DrApeman
98.9
8
GameTheory's picture
GameTheory
98.9
9
dosk17's picture
dosk17
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”